Drugs / Glutamic Acid
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00000768 | ? → Aug 1998 | HIV infectious disease, colitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00369564 | May 2007 → Nov 2012 | kidney cancer, leukemia, lymphoma, peripheral neuropathy +2 | University of South Florida | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05221892 | Nov 2021 → Mar 2023 | — | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00980408 Comparator | Jun 2008 → Aug 2011 | — | University Hospital, Bonn | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glutamic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000768 ↗ |
| Known as | DCS | “A promising candidate in this respect is the NMDAR glycine-binding site partial agonist D-cycloserine (DCS).” PMID 20303474 ↗ Mar 2010 |
| Known as | DCycloserin | “with Cycloserine® (King Pharmaceuticals Ltd, active ingredient: DCycloserin, dose: 250 mg)” NCT00980408 ↗ |
| Action | Activate | “NMDAR glycine-binding site partial agonist” PMID 20303474 ↗ Mar 2010 |
| Route | Oral | “with oral glutamic acid hydrochloride” NCT00000768 ↗ |